Olema Pharmaceuticals (OLMA) Liabilities and Shareholders Equity (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $530.6 million in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $530.6 million, up 29.54% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.8 billion (up 33.69% YoY), and the FY2025 annual result was $533.4 million, up 18.28% from the prior year.
• Liabilities and Shareholders Equity eased to $530.6 million in Q1 2026 per OLMA's latest filing, from $533.4 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $533.4 million in Q4 2025 and troughed at $177.6 million in Q2 2023.
• A 5-year average of $313.3 million and a median of $276.9 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2023 and 2024: Liabilities and Shareholders Equity dropped 29.43% in 2023, then jumped 62.84% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $215.6 million in 2022, then increased by 28.43% to $276.9 million in 2023, then soared by 62.84% to $451.0 million in 2024, then climbed by 18.28% to $533.4 million in 2025, then decreased by 0.52% to $530.6 million in 2026.
• Business Quant data shows OLMA's Liabilities and Shareholders Equity at $530.6 million in Q1 2026, $533.4 million in Q4 2025, and $352.5 million in Q3 2025.